clinical trials to support benefits18 Dec 2014 08:34
I do find this particular aspect of the r n s very surprising...
I thought this would already have been in place prior to launch in the stock market.
On my radar, but looking very weak at the moment...
Section 6. Income Tax Expense - Any ideas what this is in relation to?
No deferred tax asset has been recognised in relation to trading loss carried forward of £83 million (FY 2013: £77 million).
Hi Copout...
Anther set of fine results....expected costs to rise but as you say agree these will need to be watch otherwise will eat into the margins.
Cash burn from 13.4m to 9.4m ...which is in line with the acquisitions such as Baydonhill.
Received cash injection of 27m in September 2014....so expect more land grabbing activities in different regions.
Admin expenses increase by c£5m from last year - primarily due to Baydonhill ...it states. . and as such increases in staffing costs as headcount has increased.